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Abstract
Background: Treg based immunotherapy is of great interest to facilitate tolerance in autoimmunity and transplantation. For
clinical trials, it is essential to have a clinical grade Treg isolation protocol in accordance with Good Manufacturing Practice
(GMP) guidelines. To obtain sufficient Treg for immunotherapy, subsequent ex vivo expansion might be needed.
Methodology/Principal Findings: Treg were isolated from leukapheresis products by CliniMACS based GMP isolation
strategies, using anti-CD25, anti-CD8 and anti-CD19 coated microbeads. CliniMACS isolation procedures led to 40–60% pure
CD4
posCD25
highFoxP3
pos Treg populations that were anergic and had moderate suppressive activity. Such CliniMACS
isolated Treg populations could be expanded with maintenance of suppressive function. Alloantigen stimulated expansion
caused an enrichment of alloantigen-specific Treg. Depletion of unwanted CD19
pos cells during CliniMACS Treg isolation
proved necessary to prevent B-cell outgrowth during expansion. CD4
posCD127
pos conventional T cells were the major
contaminating cell type in CliniMACS isolated Treg populations. Depletion of CD127
pos cells improved the purity of
CD4
posCD25
highFoxP3
pos Treg in CliniMACS isolated cell populations to approximately 90%. Expanded CD127
neg CliniMACS
isolated Treg populations showed very potent suppressive capacity and high FoxP3 expression. Furthermore, our data show
that cryopreservation of CliniMACS isolated Treg is feasible, but that activation after thawing is necessary to restore
suppressive potential.
Conclusions/Significance: The feasibility of Treg based therapy is widely accepted, provided that tailor-made clinical grade
procedures for isolation and ex vivo cell handling are available. We here provide further support for this approach by
showing that a high Treg purity can be reached, and that isolated cells can be cryopreserved and expanded successfully.
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Introduction
Regulatory T cells (Treg) play a critical role in various
immunological processes, particularly in maintaining homeostasis
and self-tolerance. Immunotherapy based on Treg infusion is
therefore a potential treatment for many immune disorders. This
approach has been proven successful in animal models of stem cell
transplantation [1–7], solid organ transplantation [8,9] and auto-
immunity [6,10–13]. Therapeutic application in humans requires
large numbers of Treg, that have to be isolated and, if necessary,
expanded using clinical grade (Good Manufacturing Practice,
GMP) protocols. The CliniMACS system provides a relatively
versatile method for GMP cell isolation and is able to manage
large quantities of cells, for example from leukapheresis material.
Other authors have recently shown the feasibility of CliniMACS
for CD4
posCD25
high Treg enrichment, but failed to achieve Treg
purity of more than 40–60% [14,15]. For stem cell transplantation
recipients, a suboptimal Treg purity is unlikely to be harmful.
Currently, many stem cell transplantation recipients are treated
with donor lymphocyte infusions to enhance graft-versus-leuke-
mia/tumor responses. The main adverse effect of this treatment is
graft-versus-host-disease (GVHD). The aim of Treg immunother-
apy in this patient group is to reduce these graft-versus-host
responses. Co-infusion of both non-regulatory T cells to ensure
graft-versus-leukemia/tumor responses and Treg to prevent
excessive GVHD is therefore a logical approach in this setting.
However, in other patient groups, such as solid organ graft
recipients and patients with auto-immune diseases, high purity of
Treg for immunotherapy is crucial. Infusion of non-regulatory
cells into patients that already suffer from unwanted immunolog-
ical activity should be prevented, as these cells can potentially
intensify the disease process. The main aggressive cell types in
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pos T cells and CD4
pos
conventional T cells, and contamination of CliniMACS isolated
Treg populations with these cells should be avoided for
immunotherapy in patients other than stem cell recipients.
Likewise, contamination of the isolate with B cells could lead to
the infusion of activated B cells with potential adverse immuno-
logical consequences.
Although CliniMACS based Treg isolation from leukapheresis
products will yield large numbers of Treg, ex vivo expansion of
these cells prior to infusion might still be necessary to obtain
sufficient numbers of Treg for effective immunotherapy. Treg can
be expanded efficiently using polyclonal stimulation [16–19].
However, antigen-specific Treg have been shown to be far more
efficient than polyclonal Treg in animal models [3,5–7,12,13]. In
allogeneic transplantation, the target antigens are known (mainly
foreign HLA) and human alloantigen-specific Treg can be
obtained by expansion using stimulation with alloantigen [20,21].
For practical reasons, it would be convenient or even necessary
to perform the leukapheresis procedure weeks/months before the
transplantation or treatment and store the Treg until they are
needed. Currently, information on cryopreservation of Treg is
lacking.
In the current study, we confirm that GMP Treg isolation using
standard CliniMACS procedures results in moderately pure Treg
populations. Here, we show that purity of CliniMACS isolated
Treg can be improved by depletion of CD127
pos cells. In addition,
we show that CliniMACS isolated Treg can be expanded with
maintenance of suppressive function using polyclonal or alloanti-
gen stimuli in the presence of IL-2. Depletion of CD19
pos B cells
during CliniMACS Treg isolation appears to be a prerequisite to
prevent B cell outgrowth during expansion. Furthermore, we show
that cryopreservation of Treg is feasible, but that the cells require
activation to restore suppressive potential.
Results
Isolation of Treg using CliniMACS yields 40–60% pure
CD4
posCD25
high Treg populations with suppressive
activity
Treg immunotherapy will demand very high numbers of highly
pure Treg populations isolated in a GMP manner. To obtain large
numbers of Treg with optimal purity, we performed
CD4
posCD25
high T cell isolation from healthy donor leukapheresis
products using the GMP CliniMACS system. The most straight-
forward strategy to enrich for Treg would be a one step positive
selection of CD25
pos cells out of leukapheresis products. However,
this strategy would unintentionally result in contaminating
(activated) cytotoxic CD8
pos T cells in the isolated Treg
populations. Therefore, our initial CliniMACS isolation strategy
consisted of two steps: first a CD8 depletion step to exclude
CD8
pos effector T cells from the isolated cell populations, followed
by a CD25 enrichment step to enrich for CD4
posCD25
high Treg
(referred to as CliniMACS
8/25). For comparison, a laboratory
scale MiniMACS based Treg isolation protocol was also
performed (referred to as MiniMACS).
Leukapheresis products contained on average 3%
CD4
posCD25
high regulatory T cells (Figure 1 and Table 1). Less
than 0.1% CD8
pos cells were present in the isolated CliniMACS
8/
25 populations. While 80% of CliniMACS
8/25 cells was
CD4
posCD25
pos, only 40–60% was CD4
posCD25
high (Figure 1A
and Table 1). MiniMACS based Treg isolation from the same
leukapheresis product yielded a higher Treg purity with 90%
CD4
posCD25
high cells. CliniMACS
8/25 populations expressed
lower levels of FoxP3 as compared to MiniMACS isolated Treg
populations (Figure 1A).
A hallmark of CD4
posCD25
high Treg is their anergic phenotype,
defined as low proliferative capacity upon T cell receptor
stimulation alone as compared to Tconv cells, which can be
restored by the addition of exogenous IL-2. Both CliniMACS
8/25
and MiniMACS populations were anergic (Figure 1B).
Suppressive capacity of Treg populations was determined by
titration of Treg into co-cultures of autologous CD4
posCD25
neg
responder T cells stimulated with allogeneic stimulator PBMC. As
shown in Figure 1C, Treg populations isolated with the
CliniMACS
8/25 strategy were moderately suppressive, reaching
50% suppression at a 1:1 Tresp:Treg ratio, while MiniMACS
isolated Treg populations were more potent, with 50% suppression
at Tresp:Treg ratios of approximately 4:1.
Expansion of CliniMACS Treg with either polyclonal or
alloantigen stimulation increases cell numbers while
suppressive activity is retained
CliniMACS Treg isolation strategies yield high numbers of
Treg, but these numbers might still be too low for therapeutic
purposes. This issue can be overcome by ex vivo expansion of Treg.
To analyze expansion potential and effects of expansion on
phenotypic and functional characteristics, CliniMACS
8/25 isolated
Treg populations were activated using either polyclonal stimula-
tion (anti-CD3+anti-CD28 mAb coated microbeads) or alloanti-
gen stimulation (irradiated PBMC from an HLA-mismatched
donor), in the presence of exogenous IL-2.
Polyclonal and alloantigen stimulated expansion cultures
yielded similar cell numbers (Table 2). CliniMACS
8/25 popula-
tions increased about 30-fold in cell numbers in ten days. The
phenotype of expanded CliniMACS
8/25 populations is depicted in
Figure 2A. CD25 expression was high in both CliniMACS
8/25 and
MiniMACS populations, while the expression of FoxP3 was lower
in expanded CliniMACS
8/25 cells as compared to expanded
MiniMACS populations. After expansion, all Treg populations
remained anergic (Figure 2B). CliniMACS
8/25 and MiniMACS
populations suppressed alloantigen driven responder T cell
proliferation to a similar extent (Figure 2C). Notably, alloantigen
expanded Treg populations showed higher suppressive capacity in
alloantigen driven responder T cell responses as compared to
polyclonally expanded Treg (.75% suppression at a Tresp:Treg
ratio of 16:1 versus 50% suppression at Tresp:Treg ratios a
Tresp:Treg ratio of 8:1, respectively, Figure 2C). This indicates
that the alloantigen expanded cell populations were enriched for
alloantigen-specific Treg. As our group has shown previously, the
low proliferation observed after addition of alloantigen expanded
Tconv can be explained by distinct culture kinetics with an earlier
proliferation peak and a net result of lower counts at day 5 [21].
It would be convenient for Treg immunotherapy to be able to
store Treg cells prior to manipulation and/or infusion. The
suppressive capacity of cryopreserved CliniMACS Treg was
impaired (Figure 3), and could not be regained by cell resting
for up to seven days in culture medium. However, expansion of
cryopreserved CliniMACS cells restored suppressive capacity.
Depletion of CD19
pos cells during CliniMACS Treg
isolation is necessary to prevent B cell contamination
After CliniMACS
8/25 isolation procedures, less than 3% B cells
were present in isolated populations, these numbers increased after
expansion to 5 to 10% (Figure 4A). In order to remove B cells from
our CliniMACS isolated Treg populations, we tested the efficacy
of CD19
pos B cell depletion in the CliniMACS isolation procedure.
Clinical Grade Treg
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pos and CD19
pos cells were depleted,
followed by enrichment of CD25
pos cells (referred to as
CliniMACS
8/19/25). Less than 0.5% B cells were present after
these isolations (see Table 1 and Figure 4B) and no substantial B
cell contaminations arose after either polyclonal or alloantigen
expansion (see Table 2 and Figure 4B). CliniMACS
8/19/25
populations were similar to CliniMACS
8/25 cells with respect to
the phenotype, anergic state and suppressive potential, both
directly after isolation as well as after expansion (data not shown).
Thus, CD19
pos depletion effectively prevents B cell contamina-
tions in CliniMACS Treg populations after isolation and after
expansion.
Depletion of CD127
pos cells improves CliniMACS Treg
purity
CD4
posCD25
neg/lowFoxP3
neg/low Tconv cells were the major
contaminating cell type in CliniMACS isolated Treg (40–60% of
the isolated populations, see Figure 1). Recently, it has been
described that Tconv express the IL-7 receptor alpha-chain
CD127, while Treg cells do not express CD127 [22,23]. Indeed,
Figure 1. Phenotypic and functional characteristics of freshly CliniMACS isolated Treg. Treg were isolated from leukapheresis products in
GMP CliniMACS-based or non-GMP MiniMACS-based isolation procedures. Data from a typical isolation are shown (N=3). (A) Cell surface expression
of CD4 and CD25 and intracellular expression of FoxP3. (B) Proliferative capacity upon stimulation with allogeneic PBMC in the absence or presence of
exogenous IL-2, measured at day 5 of culture. (C) Suppressive capacity in co-cultures of autologous naı ¨ve CD4
posCD25
neg Tresp stimulated with
allogeneic PBMC. Significant differences are indicated by asterisks. In figure C, open and filled asterisks refer to Tconv (used as control for the addition
of cells) versus MiniMACS or CliniMACS
8/25, respectively.
doi:10.1371/journal.pone.0003161.g001
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neg and
CD127
pos cells, reflecting the presence of both Treg and Tconv
cells (Figure 5A). To improve the purity of Treg isolated with
CliniMACS, we hypothesized that depletion of CD127
pos cells
could be employed to exclude contaminating T cells. Because anti-
CD127 CliniMACS beads are currently not available, we depleted
CD127
pos cells from CliniMACS isolated cell populations by
FACS.
As shown in Figure 5A, this procedure indeed enabled
separation of Treg from Tconv cells. In contrast to CD127
pos
cells, the majority of CliniMACS CD127
neg cells showed a Treg
phenotype: CD4
posCD25
high and FoxP3
pos. Since we used
cryopreserved CliniMACS populations for these experiments, we
expanded the populations prior to functional characterization.
After expansion, CD127
neg populations retained a high Treg
purity, as evidenced by high expression of CD25 and FoxP3
(Figure 5B). In contrast to CD127
pos populations, CD127
neg
populations were anergic after expansion (Figure 5C). As expected,
CD127 depletion enhanced suppressive potential, as shown by the
significantly higher suppressive capacity of CD127
neg populations
as compared to CliniMACS populations that were not depleted of
CD127
pos cells (Figure 5D).
Discussion
Immunotherapy using ex vivo activated and/or expanded
CD4
posCD25
high regulatory T cells appears promising, not only
in stem cell transplantation, but also for a number of autoimmune
disorders. To be optimally effective, the availability of tailor-made
clinical grade procedures is a prerequisite. As previously reported
[14,15], CliniMACS GMP Treg isolation strategies based on
CD25
pos enrichment typically result in 40–60% pure Treg with
moderate suppressive activity.
The degree of purity of Treg that is required may depend on the
actual application. In stem cell transplantation, the first clinical
trials on Treg immunotherapy have recently been initiated. In
these studies, either CliniMACS isolated CD4
posCD25
high Treg
(with 40–60% purity) or ex vivo manipulated CD4
pos T cell lines
consisting of 5–10% induced regulatory Tr1 cells and conse-
quently a substantial amount of non-Treg were infused in patients
receiving stem cell transplantations [24]. So far, to our knowledge,
no adverse effects have been reported. However, caution is
necessary when applying Treg for auto-immune disease or solid
organ transplant purposes. Here an inadvertently present effector
pool might cause serious pathology.
As cytotoxic CD8
pos T cells are a potentially aggressive cell type
in immune responses, it is highly recommendable to exclude these
cells from CliniMACS isolated Treg populations. Here, we show
that the CD8
pos CliniMACS cell depletion step was effective: less
than 0.1% CD8
pos cells were present in isolated Treg populations,
and no outgrowth of CD8
pos cells occurred after expansion of
CliniMACS Treg populations. Treg isolated by CD25
pos enrich-
ment following CD8
pos depletion contained a small contamination
of B cells (1–3%), which could increase to up to 10% after T cell
expansion. The risks of infusion of expanded and activated
autologous B cells are unknown, but could in theory include the
development of a B cell lymphoproliferative disorder that can
occur after transplantation and is often lethal [25–27]. We were
able to prevent the contamination by B cells by including a
CD19
pos B cell depletion step in the isolation strategy.
Notwithstanding the favorable effects of combined anti-CD25,
anti-CD8 and anti-CD19 microbead isolation (the currently
available clinical grade tools), the isolated Treg population was
of suboptimal purity. Most of the contaminating cells appeared to
be CD4
posCD25
neg/low Tconv cells that could potentially lead to
immunopathology. To further improve CliniMACS Treg purity,
Wichlan et al. studied titration of anti-CD25 microbeads in the
enrichment phase of CliniMACS Treg isolation. While the use of
lower amounts of beads indeed led to populations with higher
CD25 expression levels [15], the suppressive capacity of the
isolated populations did not improve and cell yields were
significantly lower, indicating that titration of CD25 microbeads
will not provide the solution to achieve higher purity for
CliniMACS Treg isolation. These authors also reported that
adjustment of CliniMACS flow rates did not lead to a higher Treg
purity. Hoffmann et al. used three consecutive CliniMACS
selection cycles for CD25
pos cells, to preferentially select CD25
high
Treg and exclude CD25
neg/low Tconv [14]. However, the degree
of Treg purity obtained with this approach was similar to that
achieved with one CD25 enrichment cycle.
Table 1. Enrichment of CD4
posCD25
high Treg by CliniMACS isolation.
Number of WBC610
8 (SD) Percentage of cells with indicated phenotype (SD)
CD4
pos CD4
pos CD4
pos CD8
pos CD20
pos
CD25
high CD25
pos T cell T cell B cell
Leukapheresis
* 27.2 (1.9) 3 (3) 8 (8) 60 (1) 26 (7) 16 (15)
CliniMACS
8/25 1.5 (0.0) 45 (19) 78 (0) 95 (1) 0 (0) 2 (1)
CliniMACS
8/19/25 1.3 (0.1) 46 (13) 81 (5) 97 (1) 0 (0) 0 (0)
MiniMACS - 88 (2) 90 (1) 98 (0) 1 (1) 1 (1)
N=3.
*Partial leukapheresis products were used.
doi:10.1371/journal.pone.0003161.t001
Table 2. Increase in CliniMACS Treg numbers by expansion.
Polyclonal Alloantigen
CliniMACS
8/25 31 (16) 28 (14)
CliniMACS
8/19/25 34 (17) 34 (11)
MiniMACS 4 (0) 9 (3)
Tconv 46 (1) 55 (10)
Fold increase in cell numbers (SD) after 10 days expansion with indicated
stimulus in the presence of exogenous IL-2, N=3.
doi:10.1371/journal.pone.0003161.t002
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PLoS ONE | www.plosone.org 4 September 2008 | Volume 3 | Issue 9 | e3161Figure 2. Phenotypic and functional characteristics of expanded CliniMACS isolated Treg. Cell populations were expanded with
polyclonal stimulus or alloantigen stimulus in the presence of exogenous IL-2. Data from a typical experiment are shown (N=3). (A) Cell surface
expression of CD25 and intracellular expression of FoxP3. (B) Proliferative capacity upon restimulation with allogeneic PBMC (same donor as in
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receptor alpha chain CD127, while Treg do not express this
molecule [22,23]. Thus, in the current study, we hypothesized that
the conventional T cells contaminating GMP Treg populations
could be excluded from the CliniMACS isolated populations by
depleting CD127
pos cells. Since anti-CD127-microbeads for use in
CliniMACS are currently not available, we depleted CD127
pos
cells from CliniMACS isolated Treg populations by FACS. This
procedure indeed increased Treg purity, as shown by uniformly
high expression of FoxP3 in CD127
neg populations. After
expansion of CliniMACS CD127
neg populations, high expression
of FoxP3
pos was maintained, and the cell populations showed
potent suppressive capacity. Notably, suppressive capacity of
CliniMACS CD127
neg populations was significantly higher than
that of non-depleted CliniMACS populations, indicating that
CD127 depletion clearly enriched for functional Treg.
The outcome of a particular T cell based immune response is
likely to be determined by the balance between the effector and
regulatory T cell pools. Consequently, the efficacy of Treg therapy
may be determined by the actual number of antigen reactive Treg
within the infused cell population. Indeed, antigen-specific Treg
were proven to be more efficient than polyclonal Treg in
preclinical mouse models of autoimmunity [6,12,13] and graft-
versus-host disease [3,5,7]. Previously, we and others have shown
that human Treg isolated by non-clinical grade strategies can be
expanded using both polyclonal and alloantigen stimulation
methods [16–21]. Importantly, we show in this report that this
also holds true for clinical grade isolated Treg. Due to the
moderate purity of CliniMACS isolated Treg populations,
outgrowth of contaminating cells could be a risk upon expansion.
Indeed, expanded CliniMACS
8/19/25 Treg populations contained
a significant percentage of FoxP3
neg cells, however, this could be
prevented by depletion of CD127
pos cells from the CliniMACS
isolated Treg populations.
Clinical implementation of Treg based therapy will be highly
facilitated if Treg can be stored prior to infusion, as this will allow
a more flexible timing of Treg therapy and/or therapeutic
schemes with multiple Treg treatments over time. We studied
the feasibility of CliniMACS Treg cryopreservation in liquid
nitrogen. Results indicate that Treg can survive cryopreservation,
as thawed populations showed 70–80% cell viability. We noted
decreased suppressive activity of thawed Treg populations, which
could be restored by Treg expansion. An alternative approach
would be to expand Treg prior to cryopreservation. This resulted
in unaltered suppressive capacity upon thawing, at least in
MiniMACS isolated Treg (Supplemental data, Figure S1).
In summary, we here provide further support for clinical
implementation of Treg immunotherapy by showing that a high
Treg purity can be reached, and that isolated cells can be
cryopreserved and expanded successfully.
Materials and Methods
Human cells
Healthy donors were scheduled for leukapheresis procedures to
obtain leukocytes for donor lymphocyte infusions in hematopoietic
stem cell transplantation patients in the Radboud University
Nijmegen Medical Centre. Excess leukapheresis material was used
for the current study upon written informed consent with regard to
scientific use. Buffy coats from healthy human donors were
purchased from Sanquin bloodbank, Nijmegen, The Netherlands,
upon written informed consent with regard to scientific use and
used as a source of stimulator PBMC. The current study did not
require approval from an ethics committee according to the Dutch
Medical Research Involving Human Subjects Act.
Treg isolation
Healthy donor leukapheresis products were used for Clin-
iMACS CD4
posCD25
high Treg isolation. Cells were washed with
PBS/EDTA buffer (Miltenyi Biotec, Bergisch-Gladbach, Ger-
many, supplemented with 0.5% HSA (Sanquin bloodbank). Anti-
CD8 and/or anti-CD19 coated CliniMACS microbeads (kindly
provided by Miltenyi Biotec) were added, incubated for 30 min-
utes and washed. CliniMACS program 2.1 was run to deplete
labeled cells (CliniMACS separation columns were kindly
provided by Miltenyi Biotec). The labeling procedure was
repeated with anti-CD25 CliniMACS microbeads, and Clini-
MACS program 1.1 was run to enrich for CD25
pos cells.
A non-GMP MiniMACS based CD4
posCD25
high Treg isolation
method was performed on leukocytes from the same leukapheresis
products as used for CliniMACS Treg isolation. PBMC were
alloantigen expansion) in the absence or presence of exogenous IL-2, measured at day 3 of culture. (C) Suppressive capacity in co-cultures of
autologous naı ¨ve CD4
posCD25
neg Tresp stimulated with allogeneic PBMC (same donor as in alloantigen expansion). Significant differences are
indicated by asterisks. In figure C, open and filled asterisks refer to Tconv (expanded with same stimulus as Treg populations) versus MiniMACS or
CliniMACS
8/25, respectively.
doi:10.1371/journal.pone.0003161.g002
Figure 3. Cryopreservation of CliniMACS Treg affects suppres-
sive capacity, which can be restored by activation. Suppressive
capacity of cryopreserved CliniMACS Treg in co-cultures of autologous
naı ¨ve CD4
posCD25
neg Tresp stimulated with allogeneic PBMC. Data from
a typical experiment are shown (N=2–4). Prior to co-culture
suppression assay, indicated cell populations were expanded for 10
days in the presence of exogenous IL-2 and allogeneic PBMC (same
donor as in co-culture suppression assay). Significant differences are
indicated by asterisks. Open and filled asterisks refer to cryopreserva-
tion versus cryopreservation plus 4 days rest or cryopreservation plus
expansion, respectively.
doi:10.1371/journal.pone.0003161.g003
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comed Pharma, Roskilde, Denmark). CD4
pos T cells were
negatively selected using mAbs directed against CD8 (RPA-T8),
CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33 (P67.6), CD235a
(GA-R2(HIR2) (BD Biosciences, San Jose, CA, USA), and CD56
(MOC-1) (Dako, Glostrup, Denmark) combined with sheep-anti-
mouse-IgG coated magnetic beads (Dynal Biotech, Oslo, Norway),
routinely resulting in a .90% pure CD4
pos T cell fraction.
CD25
high Treg and CD25
neg conventional T cells (referred to as
Tconv, included in all experiments as control cell population) were
separated by MACS-sorting, using 10 ml anti-CD25 magnetic
microbeads/10
7 CD4
pos cells (Miltenyi Biotec).
For CD127
pos cell depletion, CliniMACS isolated Treg were
stained with anti-CD127-AlexaFluor647 (BD Biosciences) and
CD127
pos cells were depleted on an Elite FACS machine
(Beckman Coulter, Fullerton, CA, USA).
Stimulator PBMC were isolated from healthy donor buffy coat
by density gradient centrifugation (Lymphoprep, Nycomed
Pharma).
HLA typing was performed by serological and DNA based
techniques according to international (ASHI/EFI) standards [28].
Treg cryopreservation
Treg cells were suspended in RPMI 1640 supplemented with
pyruvate (0,02 mM), penicillin (100 U/ml), streptomycin (100 mg/
ml), 20% human pooled serum (HPS) and 15% dimethylsulfoxide,
were kept in 280uC for one week, and were subsequently
transferred to liquid nitrogen for up to one year. Cells were quickly
thawed in a 37uC water bath and washed twice before use.
Treg expansion
Cell cultures were performed in culture medium consisting of
RPMI 1640 supplemented with pyruvate (0.02 mM), penicillin
(100 U/ml), streptomycin (100 mg/ml), 10% HPS and IL-2
(25 U/ml, Chiron, Amsterdam, the Netherlands) with 5610
4 cells
per well in 96-well round bottom plates, in a 37uC, 95% humidity,
5% CO2 incubator. Stimulation was provided by either 10
5
irradiated (30 Gy) fully HLA-mismatched allogeneic PBMC per
Figure 4. B cell contamination can be prevented by depleting CD19
pos cells during CliniMACS Treg isolation. Percentage of
contaminating B cells in freshly isolated or alloantigen expanded CliniMACS populations. Data from a typical experiment are shown (N=3). (A)
CliniMACS
8/25 populations. (B) CliniMACS
8/19/25 populations.
doi:10.1371/journal.pone.0003161.g004
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pos Tconv cells. CliniMACS populations were stained with anti-
CD127 and sorted into CD127
neg and CD127
pos subsets. CliniMACS cells were cryopreserved prior to cell sorting. Data from one of two similar
experiments are shown. (A) Cell surface expression of CD127, CD4 and CD25 and intracellular expression of FoxP3. (B-C-D) CliniMACS populations
were expanded with alloantigen stimulation and exogenous IL-2. (B) Cell surface expression of CD25 and intracellular expression of FoxP3. (C)
Clinical Grade Treg
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4 anti-CD3+anti-CD28 mAb
coated microbeads per well (Dynal Biotech, polyclonal expansion).
Wells were split and provided with fresh medium containing
cytokines every 3 days. After 10 days, the cells were harvested,
washed and rested for 2 days in 5% HPS culture medium before
functional and phenotypic analyses.
Flow cytometry
The phenotype of cells was analyzed by five-color flow
cytometry (FC500, Beckman Coulter). For cell surface staining,
the following conjugated mAbs were used: anti-
CD4(SFCI12T4D11)-PCy7, anti-CD19(J4.119)-PE (Beckman
Coulter), anti-CD25(4E3)-biotin, anti-biotin(Bio3-18E7)-PE (used
in Figures 1 and 2), anti-CD20(LT20)-PE (Miltenyi Biotec), anti-
CD25(M-A251)-PE (used in Figure 5), and anti-CD127(hIL-7R-
M21)-AlexaFluor647 (BD Biosciences). For intracellular staining,
Fix and Fix/Perm buffer and anti-FoxP3(PCH101)-FITC were
used according to the manufacturer’s instructions (eBioscience,
San Diego, CA, USA). Isotype controls were used for gate settings.
Stimulation assay to analyze T cell anergy
T cell anergy was examined in (re-)stimulation assays.
2.5610
4 cells were stimulated with 10
5 irradiated allogeneic
stimulator PBMC in the presence or absence of IL-2 (12.5 U/
ml). Proliferation was measured at day 5 (primary responses) or
day 3 (secondary responses). To this end, 0.5 mCi [
3H]Thymidine
(Amersham Biosciences, Piscataway, NJ) was added to each well.
After 8 hours, [
3H]Thymidine incorporation was measured using
a beta-plate counter (Packard, Canberra, Australia). Tests were set
up in triplicate; results were expressed as mean+SD counts per
5 minutes.
Co-culture suppression assays
Suppressive capacity of Treg was studied in co-culture
suppression assays. 5610
4 autologous responder T cells
(CD4
posCD25
neg, Tresp) were stimulated with 10
5 irradiated
allogeneic stimulator PBMC. Treg were titrated into these
cultures. Proliferation was measured at day 5 by determination
of [
3H]Thymidine incorporation as described above. Tests were
set up in triplicate, results were expressed as mean+SD counts per
5 minutes.
Statistical analysis
Proliferative capacities of different cell populations were
compared using Student T tests. A P value,0.05 was considered
statistically significant.
Supporting Information
Figure S1 Unaffected suppressive capacity of Mini-
MACS Treg by expansion prior to cryopreservation.
Suppressive capacity of cryopreserved MiniMACS Treg isolated
from healthy donor buffy coat in co-cultures of autologous naı ¨ve
CD4
posCD25
neg Tresp stimulated with allogeneic PBMC. Data
from one of two similar experiments are shown. Prior to co-culture
suppression assay, indicated cell populations were expanded for 10
days in the presence of exogenous IL-2 and allogeneic PBMC
(same donor as in co-culture suppression assay). Significant
differences are indicated by asterisks. Open and filled asterisks
refer to cryopreservation versus cryopreservation followed by
expansion or expansion followed by cryopreservation, respectively.
Found at: doi:10.1371/journal.pone.0003161.s001 (0.12 MB TIF)
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